Compare
Emergent BioSolutions Inc. vs Pacira BioSciences, Inc. vs Amphastar Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
| Latest fiscal year | Emergent BioSolutions Inc. EBS | Pacira BioSciences, Inc. PCRX | Amphastar Pharmaceuticals, Inc. AMPH | Supernus Pharmaceuticals, Inc. SUPN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $742.90M | $726.41M | $719.89M | $718.95M |
| Revenue growth (YoY) | -28.8% | +3.6% | -1.7% | +8.6% |
| Gross margin | 56.1% (computed) | 79.4% (computed) | 49.5% | 89.6% (computed) |
| Operating margin | 13.5% | 2.6% | 19.5% | -8.7% |
| Net margin | 7.1% | 1.0% | 13.6% | -5.4% |
| Net income | $52.60M | $7.03M | $98.09M | -$38.55M |
| EPS (Diluted) | $0.93 | $0.16 | $2.03 | -$0.68 |
| Operating cash flow | $170.60M | $151.99M | $156.12M | $47.33M |
| Free cash flow | $156.80M | $136.66M | $121.23M | $45.99M |
| Cash & equivalents | $205.40M | $158.54M | $170.18M | $128.45M |
| Total assets | $1.32B | $1.26B | $1.63B | $1.45B |
| Total liabilities | $796.00M | $571.81M | $840.49M | $390.93M |
| Shareholders' equity | $522.60M | $693.11M | $788.80M | $1.06B |
| Return on year-end equity | 10.1% | 1.0% | 12.4% | -3.6% |
| Shares outstanding | 52.10M | 41.12M | 45.65M | 57.46M |
Revenue, most recent five fiscal years
| Fiscal year | Emergent BioSolutions Inc. | Pacira BioSciences, Inc. | Amphastar Pharmaceuticals, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $742.90M Ended 2025-12-31 | $726.41M Ended 2025-12-31 | $719.89M Ended 2025-12-31 | $718.95M Ended 2025-12-31 |
| 1 year earlier | $1.04B Ended 2024-12-31 | $700.97M Ended 2024-12-31 | $731.97M Ended 2024-12-31 | $661.82M Ended 2024-12-31 |
| 2 years earlier | $1.05B Ended 2023-12-31 | $674.98M Ended 2023-12-31 | $644.39M Ended 2023-12-31 | $607.52M Ended 2023-12-31 |
| 3 years earlier | $1.12B Ended 2022-12-31 | $666.82M Ended 2022-12-31 | $498.99M Ended 2022-12-31 | $667.24M Ended 2022-12-31 |
| 4 years earlier | $1.77B Ended 2021-12-31 | $541.53M Ended 2021-12-31 | $437.77M Ended 2021-12-31 | $579.77M Ended 2021-12-31 |